ITF Therapeutics
ITF Therapeutics was launched in January 2024 as the US affiliate of Italfarmaco, focusing on the development and commercialization of products to treat rare diseases. Building on a legacy grounded in collaboration and innovation, ITF Therapeutics strives to partner with leaders from the patient advocacy and treatment communities to ensure that our programs reflect and support their unique needs and goals. The establishment of ITF Therapeutics reflects Italfarmaco's goal to build a world-class team of experts who share a passion to make a positive impact for rare disease communities. For more information visit www.itftherapeutics.com.Content by ITF Therapeutics
| 4 min read
The HDAC inhibitor givinostat has received regulatory approval in the US, EU, and UK for patients six years and older.
| 4 min read
Long-term treatment with givinostat can significantly delay loss of key mobility functions in patients with DMD
Page 1 of 1 - 2 Total Items
